Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHyoju YiSHSeunghyeok HamSPSesun Park

Discussion

Loading...

Member takes

Overview

Feasibility study shows ex vivo testing predicts survival outcomes in AML patients, indicating new therapeutic strategies.

Key Points

  • To evaluate the feasibility of ex vivo drug sensitivity testing (DST) in Korean AML patients and its correlation with clinical outcomes.
  • Conducted DST on bone marrow aspirates from 58 AML patients using a viability-based assay across 21 anti-leukemic agents.
  • Identified mutations through targeted sequencing including TP53, RUNX1, and DNMT3A.
  • Analyzed the association between DST metrics and survival outcomes according to treatment regimens.
  • DST revealed high variability in drug responses among patients, particularly with venetoclax, mitoxantrone, and gilteritinib.
  • Ex vivo sensitivity to venetoclax and hypomethylating agents strongly correlated with overall survival in newly diagnosed patients.
  • Unique associations were found, such as IDH2 mutations correlating with sensitivity to sorafenib, and RUNX1 mutations with midostaurin.

Cite This Study

Yi et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcachttps://doi.org/10.1182/blood-2025-939
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia2025
  2. 2A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia2025 · 1 citations
  3. 3The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication2025
  4. 4Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML2025
  5. 5Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study2025